Amicus Therapeutics, Inc.
FOLD
$9.13
$0.232.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 23.50% | -16.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.50% | -16.34% | |||
| Cost of Revenue | 30.08% | -21.15% | |||
| Gross Profit | 22.83% | -15.81% | |||
| SG&A Expenses | -7.93% | 5.95% | |||
| Depreciation & Amortization | 0.82% | -10.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.97% | -0.40% | |||
| Operating Income | 2.26% | -149.79% | |||
| Income Before Tax | -6.30% | -327.44% | |||
| Income Tax Expenses | 43.89% | 153.50% | |||
| Earnings from Continuing Operations | -12.61% | -247.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.61% | -247.13% | |||
| EBIT | 2.26% | -149.79% | |||
| EBITDA | 3.19% | -133.95% | |||
| EPS Basic | -12.34% | -246.57% | |||
| Normalized Basic EPS | 3.54% | -326.54% | |||
| EPS Diluted | -12.34% | -246.57% | |||
| Normalized Diluted EPS | 3.54% | -326.54% | |||
| Average Basic Shares Outstanding | 0.18% | 0.50% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||